Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations for 2005 : hearings before a subcommittee of the Committee on Appropriations, House of Representatives, One Hundred Eighth Congress, second session /

Shipping list no.: 2004-0116-P (pts. 1A-B), 2004-0162-P (pt.2), 2004-0180-P (pt. 3), 2004-0204-P (pt. 4), 2004-0198-P (pt. 5), 2004-0199-P (pt. 6), 2004-0207-P (pt. 7), 2004-0208-P (pt. 8).

Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations for 2006 : hearings before a Subcommittee of the Committee on Appropriations, House of Representatives, One Hundred Ninth Congress, first session /

Shipping list no. : 2005-0156-P (pt. 1A), 2005-0131-P (pt. 1B), 2005-0136-P (pt. 2), 2005-0172-P (pt. 3-5, 7), 2005-0185-P (pt. 6), 2005-0168-P (pt. 8), 2006-0066-P (pt. 9).

Parathion data presented to U.S. Food and Drug Administration, in the matter of: tolerances for poisonous or deleterious residues on or in fresh fruits and vegetables.

Cover-title.

Report of the Special Counsel's investigation of allegations relating to the Bureau of Veterinary Medicine, Food and Drug Administration /

Cover title.

Report to the Commissioner of the Food and Drug Administration by the FDA Task Force on the use of antibiotics in animal feeds.

Appended: Press briefing by Commissioner Charles C. Edwards and by C. D. Van Houweling.

The Food and drug administration of the United States Department of agriculture.

"Enforcement of Food and Drugs Act, Tea Act, Import Milk Act, Insecticide Act, Caustic Poison Act, Naval Stores Act."

Food and Drug Administration affirmative action plan.

Cover title.

Agriculture, Rural Development, Food and Drug Administration, and related agencies appropriations bill, 2007 : report (to accompany H.R. 5384).

"June 22, 2006."

Interagency coordination in drug research and regulation : hearings before the Subcommittee on Reorganization and International Organizations of the Committee on Government Operations, United States Senate, Eighty-seventh Congress, second session. Agency coordination study (pursuant to S. Res. 276, 87th Cong.). Review of cooperation on drug policies among Food and Drug Administration, National Institutes of Health, Veterans' Administration, and other agencies. ...

Pt. 4-5 titles vary: "Eighty-eighth Congress, first session. Agency Coordination Study (pursuant to S. Res. 27, 88th Cong., as amended). Review of cooperation on drug policies among (the) Food and Drug Administration, National Institutes of Health, Veterans' Administration, and other agencies.

Set-up and maintenance of syringe drivers for subcutaneous drug administration in palliative care

Focal points: Details of syringe driver use were collected from 11 inpatient hospice units in the West Midlands and compared with predetermined standards set by a multidisciplinary group We recorded 294 syringe driver events which complied with standards for the choice of administration site, protection of the syringe driver from light and the reason for initiation of the infusion Issues of nurse training, variability in prescribing practices, provision of written information for patients, labelling and documentation of the diluent used were all identified as areas in which compliance with standards could be improved

Optimization Problem in a Class of Linear System. Application to Multiple Drug Administration

2000 Mathematics Subject Classification: 62H15, 62P10.

Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.

Unacylated ghrelin (UAG) is the predominant ghrelin isoform in the circulation. Despite its inability to activate the classical ghrelin receptor, preclinical studies suggest that UAG may promote β-cell function. We hypothesized that UAG would oppose the effects of acylated ghrelin (AG) on insulin secretion and glucose tolerance. AG (1 µg/kg/h), UAG (4 µg/kg/h), combined AG+UAG, or saline were infused to 17 healthy subjects (9 men and 8 women) on four occasions in randomized order. Ghrelin was infused for 30 min to achieve steady-state levels and continued through a 3-h intravenous glucose tolerance test. The acute insulin response to glucose (AIRg), insulin sensitivity index (SI), disposition index (DI), and intravenous glucose tolerance (kg) were compared for each subject during the four infusions. AG infusion raised fasting glucose levels but had no effect on fasting plasma insulin. Compared with the saline control, AG and AG+UAG both decreased AIRg, but UAG alone had no effect. SI did not differ among the treatments. AG, but not UAG, reduced DI and kg and increased plasma growth hormone. UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid levels. UAG selectively decreased glucose and fructose consumption compared with the other treatments. In contrast to previous reports, acute administration of UAG does not have independent effects on glucose tolerance or β-cell function and neither augments nor antagonizes the effects of AG.

Tenoxicam controls pain without altering orthodontic movement of maxillary canines

Arantes GM, Arantes VMN, Ashmawi HA, Posso IP To study the efficacy of tenoxicam for pain control, its potential for preemptive analgesia, and its influence on the orthodontic movement of upper canine teeth. This was a randomized controlled double-blind cross-over study. The patients were divided into three groups. Two groups received tenoxicam in daily doses of 20 mg orally for 3 days. Group A received the first dose of the drug before orthodontic activation and group B, just afterwards. Group C (control) received a placebo for 3 days. All groups had access to 750 mg of paracetamol up to four times a day. Three orthodontic activations were performed at 30-day intervals. Each patient belonged to two different groups. Pain intensity was assessed using a descriptive Pain Scale and a Visual Analog Scale. Private clinic; 36 patients undergoing bilateral canine tooth retraction. The statistical analysis did not show any difference in movement between the active groups and the control at any time. There was no statistical difference between the groups that received tenoxicam. Pain intensity in these groups was lower than in the placebo group. The difference in pain intensity between the active groups and the control was greatest at the assessment made 12 h after activation and it tended to zero, 72 h after activation. Tenoxicam did not influence orthodontic movement of the upper canines. It was effective for pain control and did not present any preemptive analgesic effect.